AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome
Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
- Details
- Category: Novo Nordisk
Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing.
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced an innovative partnership with CrowdMed, a Web-based technology that harnesses "the wisdom of crowds" to solve difficult medical cases online. Starting January 1, 2016, CrowdMed will be offered as a pilot to US Shire employees and covered dependents.
300 million child-friendly antimalarial treatments supplied without profit by Novartis
- Details
- Category: Novartis
Novartis announced today that it has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.
AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
- Details
- Category: AstraZeneca
AstraZeneca announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis has developed the service in close clinical collaboration with AstraZeneca and the US National Cancer Institute (NCI).
Daratumumab combined with standard treatment for multiple myeloma produced deep and durable responses in relapsed or refractory patients
- Details
- Category: Johnson & Johnson
Janssen-Cilag International NV announced new data from the ongoing Phase 1/2 GEN503 investigational study showing the human CD38-directed monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, yielded an overall response rate (ORR) of 81 percent in relapsed or refractory multiple myeloma patients who had received a median of two prior therapies.
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Commission has granted marketing authorisation for Nucala® (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in adult patients. As a result Nucala is now approved for use in the 31 European countries covered by the European Medicines Agency (EMA).
More Pharma News ...
- Roche and Upsher-Smith announce license agreement to develop novel VAP-1 inhibitor
- Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M
- Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
- Roche receives EU approval of Cotellic for use in combination with Zelboraf in advanced melanoma
- AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
- Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
- Merck and Pfizer receive FDA Breakthrough Therapy designation for avelumab in metastatic Merkel cell carcinoma